A Novel Combination Therapy Using Rosuvastatin and <i>Lactobacillus</i> Combats Dextran Sodium Sulfate-Induced Colitis in High-Fat Diet-Fed Rats by Targeting the TXNIP/NLRP3 Interaction and Influencing Gut Microbiome Composition

• Main Authors: Sameh Saber (Author), Eslam E. Abd El-Fattah (Author), Galal Yahya (Author), Naglaa A. Gobba (Author), Abdalkareem Omar Maghmomeh (Author), Ahmed E. Khodir (Author), Ahmed A. E. Mourad (Author), Ahmed S. Saad (Author), Hager G. Mohammed (Author), Nehal A. Nouh (Author), Ahmed Shata (Author), Noha A. Amin (Author), Magdy Abou El-Rous (Author), Samuel Girgis (Author), Eman El-Ahwany (Author), Eman M. Khalaf (Author), Attalla F. El-Kott (Author), Ahmed M. El-Baz (Author)
• Format: Book
• Published: MDPI AG, 2021-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Inflammasome targeting and controlling dysbiosis are promising therapeutic approaches to control ulcerative colitis. This report is the first to investigate the mechanisms underlying the coloprotective effects of rosuvastatin and <i>Lactobacillus</i> and their combined therapy on dextran...